All In Biotech

Drug Trial Radar · NCT06961006

A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)

A Phase 2, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With First-Line Advanced Melanoma (INTerpath-012)

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

May 29, 2025

Primary completion

Jul 22, 2028

Study completion Sep 5, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn if intismeran autogene with pembrolizumab can stop advanced melanoma from growing or spreading. Melanoma is a type of skin cancer. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. A standard (or usual) treatment for advanced melanoma is immunotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Intismeran autogene is a study treatment designed to help a person's immune system attack their specific cancer. Pembrolizumab is an immunotherapy. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab live longer without the cancer growing or spreading than people who receive placebo with pembrolizumab. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of a study treatment.

Conditions

  • Malignant Melanoma

Interventions

  • Intismeran autogeneBiological

    IM injection

  • PembrolizumabBiological

    IV infusion

  • PlaceboOther

    IM injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to approximately 36 months

Locations

38 sites in 12 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group ( Site 4042)

    Springdale, Arkansas

  • UCSF Medical Center at Mission Bay ( Site 4044)

    San Francisco, California

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 4047)

    Hackensack, New Jersey

  • Inova Schar Cancer Institute ( Site 4046)

    Fairfax, Virginia

  • Fred Hutchinson Cancer Center ( Site 4041)

    Seattle, Washington

  • Blacktown Hospital ( Site 2001)

    Blacktown, New South Wales, Australia

  • Melanoma Institute Australia ( Site 2000)

    Wollstonecraft, New South Wales, Australia

  • One Clinical Research ( Site 2002)

    Nedlands, Western Australia, Australia

  • William Osler Health System (Brampton Civic Hospital) ( Site 2023)

    Brampton, Ontario, Canada

  • Sunnybrook Research Institute ( Site 2022)

    Toronto, Ontario, Canada

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet-Dermatology Department ( Site 2042)

    Nice, Alpes-Maritimes, France

  • Hôpital Saint-Louis ( Site 2041)

    Paris, Île-de-France Region, France

  • Gustave Roussy ( Site 2040)

    Villejuif, Île-de-France Region, France

  • Universitaetsklinikum Hamburg-Eppendorf ( Site 2060)

    Hamburg, Germany

  • NCT ( Site 2065)

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Frankfurt Goethe-Universität ( Site 2063)

    Frankfurt am Main, Hesse, Germany

  • Universitaetsklinikum Koeln ( Site 2064)

    Cologne, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Essen ( Site 2061)

    Essen, North Rhine-Westphalia, Germany

  • European Interbalkan Medical Center ( Site 2081)

    Thessaloniki, Greece

  • General Hospital of Athens "Laiko" ( Site 2080)

    Athens, Attica, Greece

  • Metropolitan Hospital ( Site 2082)

    Athens, Attica, Greece

  • HaEmek Medical Center ( Site 3003)

    Afula, Israel

  • Hadassah Medical Center ( Site 3001)

    Jerusalem, Israel

  • Rabin Medical Center ( Site 3002)

    Petah Tikva, Israel

  • Sheba Medical Center ( Site 3000)

    Ramat Gan, Israel

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 3020)

    Naples, Italy

  • Istituto Oncologico Veneto IRCCS ( Site 3022)

    Padova, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 3023)

    Roma, Italy

  • Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 3021)

    Milan, Milano, Italy

  • Harbour Cancer & Wellness ( Site 3040)

    Auckland, New Zealand

  • Uniwersytecki Szpital Kliniczny w Poznaniu ( Site 3061)

    Poznan, Greater Poland Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 3060)

    Warsaw, Masovian Voivodeship, Poland

  • Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 4001)

    Lisbon, Portugal

  • Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 4000)

    Porto, Portugal

  • Unidade Local de Saude Lisboa Ocidental - Hospital de São Francisco Xavier ( Site 4002)

    Lisbon, Lisbon District, Portugal

  • Hospital Universitari Vall d Hebron ( Site 3081)

    Barcelona, Spain

  • Hospital Clínic Barcelona ( Site 3080)

    Barcelona, Spain

  • Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 3082)

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.